NASDAQ:ABAX - Abaxis Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$83.00 0.00 (0.00 %)
(As of 08/21/2018 04:09 AM ET)
Previous Close$83.00
Today's RangeN/A
52-Week Range$43.66 - $83.98
VolumeN/A
Average Volume167,754 shs
Market Capitalization$1.90 billion
P/E Ratio64.34
Dividend Yield0.87%
Beta1.43
Abaxis logoAbaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care to provide rapid blood constituent measurements for clinicians worldwide. It operates in two segments, Medical Market and Veterinary Market. The company offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents. It also provides VetScan VS2, a chemistry, electrolyte, immunoassay, and blood gas analyzer delivering results from a sample of whole blood, serum, or plasma; VetScan profiles, which are packaged as single-use plastic veterinary reagent discs; and VetScan HM5, VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, as well as reagent kits for veterinary applications. In addition, the company offers VetScan VSpro that assists the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, disseminated intravascular coagulation evaluation, hepatic disease, monitoring therapy, and disease progression states; VetScan VSpro coagulation test to evaluate prothrombin and the activated partial thromboplastin times; VetScan VSpro fibrinogen test for in-vitro determination of fibrinogen levels in equine platelet poor plasma from a citrated stabilized whole blood sample; i-STAT that delivers blood gas, electrolyte, chemistry, and hematology results; VetScan UA, a urinalysis solution; and VetScan SA, which is designed to perform urine microscopy. Further, it provides VetScan rapid tests for the detection of various diseases, as well as sells products developed through its patented Orbos discrete lyophilization process to companies for other applications. The company sells its products through direct sales force and independent distributors. Abaxis, Inc. was founded in 1989 and is headquartered in Union City, California.

Receive ABAX News and Ratings via Email

Sign-up to receive the latest news and ratings for ABAX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Measuring & controlling devices, not elsewhere classified
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ABAX
CUSIP00256710
Phone510-675-6500

Debt

Debt-to-Equity RatioN/A
Current Ratio6.02
Quick Ratio5.02

Price-To-Earnings

Trailing P/E Ratio64.34
Forward P/E Ratio56.46
P/E Growth5.51

Sales & Book Value

Annual Sales$244.70 million
Price / Sales7.76
Cash Flow$1.7145 per share
Price / Cash48.41
Book Value$12.81 per share
Price / Book6.48

Profitability

EPS (Most Recent Fiscal Year)$1.29
Net Income$27.17 million
Net Margins11.11%
Return on Equity10.65%
Return on Assets9.12%

Miscellaneous

Employees656
Outstanding Shares22,870,000
Market Cap$1.90 billion

Abaxis (NASDAQ:ABAX) Frequently Asked Questions

What is Abaxis' stock symbol?

Abaxis trades on the NASDAQ under the ticker symbol "ABAX."

How often does Abaxis pay dividends? What is the dividend yield for Abaxis?

Abaxis announced a quarterly dividend on Thursday, April 26th. Stockholders of record on Friday, June 1st will be paid a dividend of $0.18 per share on Friday, June 15th. This represents a $0.72 annualized dividend and a dividend yield of 0.87%. The ex-dividend date of this dividend is Thursday, May 31st. This is an increase from Abaxis's previous quarterly dividend of $0.16. View Abaxis' Dividend History.

How will Abaxis' stock buyback program work?

Abaxis declared that its Board of Directors has initiated a share buyback program on Wednesday, October 25th 2017, which permits the company to repurchase $21,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's board of directors believes its shares are undervalued.

How were Abaxis' earnings last quarter?

Abaxis Inc (NASDAQ:ABAX) announced its quarterly earnings results on Thursday, April, 26th. The medical research company reported $0.42 EPS for the quarter, topping the Zacks' consensus estimate of $0.32 by $0.10. The medical research company had revenue of $67.90 million for the quarter, compared to analysts' expectations of $66.02 million. Abaxis had a return on equity of 10.65% and a net margin of 11.11%. Abaxis's revenue for the quarter was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.33 earnings per share. View Abaxis' Earnings History.

What price target have analysts set for ABAX?

9 equities research analysts have issued 1 year price objectives for Abaxis' shares. Their forecasts range from $48.00 to $65.00. On average, they expect Abaxis' stock price to reach $58.3333 in the next twelve months. This suggests that the stock has a possible downside of 29.7%. View Analyst Price Targets for Abaxis.

What is the consensus analysts' recommendation for Abaxis?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abaxis in the last year. There are currently 1 sell rating, 7 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Abaxis.

Who are some of Abaxis' key competitors?

Who are Abaxis' key executives?

Abaxis' management team includes the folowing people:
  • Mr. Clinton H. Severson, Chairman & CEO (Age 70)
  • Mr. Donald P. Wood, Pres & COO (Age 66)
  • Mr. Ross Taylor Jr., CFO, VP of Fin. & Sec. (Age 55)
  • Dr. Kenneth P. Aron Ph.D., Chief Technology Officer (Age 65)
  • Dr. Craig M. Tockman DVM, VP of Animal Health Sales and Marketing - North America (Age 58)

Has Abaxis been receiving favorable news coverage?

News coverage about ABAX stock has trended somewhat positive recently, Accern reports. The research group ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Abaxis earned a coverage optimism score of 0.09 on Accern's scale. They also gave news headlines about the medical research company an impact score of 47.21 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View Recent Headlines for Abaxis.

Who are Abaxis' major shareholders?

Abaxis' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.52%), Dimensional Fund Advisors LP (3.08%), Wells Fargo & Company MN (2.21%), Nuance Investments LLC (1.79%), Bank of New York Mellon Corp (1.41%) and Renaissance Technologies LLC (1.25%). Company insiders that own Abaxis stock include Achim Henkel, Clinton Severson, Craig Tockman, Donald Peter Wood, Kenneth Aron, Michael D Casey, Prithipal Singh and Richard Bastiani. View Institutional Ownership Trends for Abaxis.

Which major investors are selling Abaxis stock?

ABAX stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Russell Investments Group Ltd., AMI Asset Management Corp, US Bancorp DE, Millennium Management LLC, Bank of New York Mellon Corp, Bard Associates Inc. and Pinebridge Investments L.P.. Company insiders that have sold Abaxis company stock in the last year include Achim Henkel, Craig Tockman, Donald Peter Wood, Kenneth Aron, Michael D Casey and Prithipal Singh. View Insider Buying and Selling for Abaxis.

Which major investors are buying Abaxis stock?

ABAX stock was bought by a variety of institutional investors in the last quarter, including Nuance Investments LLC, Gabelli Funds LLC, BlackRock Inc., Renaissance Technologies LLC, Gamco Investors INC. ET AL, Capital Fund Management S.A., IndexIQ Advisors LLC and Water Island Capital LLC. View Insider Buying and Selling for Abaxis.

How do I buy shares of Abaxis?

Shares of ABAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abaxis' stock price today?

One share of ABAX stock can currently be purchased for approximately $83.00.

How big of a company is Abaxis?

Abaxis has a market capitalization of $1.90 billion and generates $244.70 million in revenue each year. The medical research company earns $27.17 million in net income (profit) each year or $1.29 on an earnings per share basis. Abaxis employs 656 workers across the globe.

How can I contact Abaxis?

Abaxis' mailing address is 3240 WHIPPLE ROAD, UNION CITY CA, 94587. The medical research company can be reached via phone at 510-675-6500 or via email at [email protected]


MarketBeat Community Rating for Abaxis (NASDAQ ABAX)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  188 (Vote Outperform)
Underperform Votes:  305 (Vote Underperform)
Total Votes:  493
MarketBeat's community ratings are surveys of what our community members think about Abaxis and other stocks. Vote "Outperform" if you believe ABAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel